Intravitreal Triamcinolone Injection in Patients With Surgically Controlled Glaucoma | Glaucoma | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Sign In
Clinicopathologic Reports, Case Reports, and Small Case Series
December 2006

Intravitreal Triamcinolone Injection in Patients With Surgically Controlled Glaucoma

Arch Ophthalmol. 2006;124(12):1788-1790. doi:10.1001/archopht.124.12.1788

In recent years, intravitreal triamcinolone acetonide (IVT) injection has emerged as an important therapeutic modality and has been evaluated as treatment of a large range of macular pathologic abnormalities, including cystoid macular edema, choroidal neovascularization, and diabetic macular edema.1-3 Even though the functional and anatomical improvement observed is promising, in particular when treating macular edema, the therapeutic efficacy is somewhat shadowed by the finding that IVT treatment also results in elevated intraocular pressure (IOP) in approximately 40% of eyes treated.4 High baseline IOP and history of glaucoma are associated with greater incidence of post-IVT IOP elevation, and as many as 50% of glaucomatous eyes have been reported to develop an IOP of 24 mm Hg or greater following the procedure.4,5 This observation has led to a common practice of considering glaucoma as a relative contraindication to using IVT for treatment of cystoid macular edema, diabetic macular edema, or choroidal neovascularization. Given the limited therapeutic options available for those maculopathies, and considering that in patients with pre-existing glaucoma the peripheral vision is also under serious threat, we believe that the concept of treating glaucomatous eyes with IVT is worth reconsidering. Herein, we report the clinical course of 11 patients with glaucoma who subsequently developed macular disease and were injected with 4 mg of triamcinolone acetonide.

Nine patients had undergone filtering surgery between 2 weeks and 12 years before their first IVT injection, and all blebs and shunts were assessed to be functional at the time of triamcinolone treatment. Follow-up period in this study ranged from 3 to 13 months; visual acuity (VA) changes reported were calculated using the baseline VA and the VA recorded at the last visit. The maximum increase of IOP after administering IVT to eyes with surgically controlled glaucoma was 6 mm Hg; the mean difference between pre-IVT and maximum post-IVT IOP was 1 mm Hg. Two patients required additional medication to achieve control of their IOP (patients 2 and 6 in the Table); 3 others were already receiving topical medications, which were continued following IVT. All but 1 subject showed at least short-term improvement in their visual function as well as anatomical regression of macular lesion. The clinical characteristics of the patients, their responses to IVT, and the measures used to achieve IOP control are summarized in the Table; in addition, the clinical course of 2 patients treated with triamcinolone before and after filtering surgery is described.

Patients' Clinical Characteristics and Response to Intravitreal Triamcinolone Injection
Patients' Clinical Characteristics and Response to Intravitreal Triamcinolone Injection

Report of Cases

Case 1. An otherwise healthy 96-year-old man (patient 1) with a history of primary open-angle glaucoma controlled with travaprost and dorzolamide complained of recently deteriorating vision in his left eye; his right eye had reportedly had very poor vision for 60 years. Visual acuity was 20/400 OD and 20/60 OS. The diagnosis was central retinal vein occlusion in the left eye; its IOP at the time was 16 mm Hg. Optical coherence tomography revealed cystoid macular edema and a central macular thickness of 376 μm. Three weeks later, his vision deteriorated to 20/200 and macular thickness increased to 548 μm. The decision was made to treat him with IVT. Four weeks later, his vision had improved to 20/80, his macular thickness was 234 μm, and his IOP was elevated at 24 mm Hg. During the following 3 months, his VA remained stable, but his IOP was above normal despite medical treatment, reaching a maximum of 34 mm Hg. Four months after IVT, the cystoid macular edema recurred and the patient's VA deteriorated to 20/150. Since adequate control of IOP had not been achieved, a second IVT was deemed unacceptable despite favorable visual outcome after the first treatment. To facilitate further steroid treatment, the patient elected to undergo trabeculectomy 2 months later (7 months after the first triamcinolone injection) after his vision deteriorated to counting fingers and an additional IVT injection was given. His IOP at the last visit (5 months postinjection) was 7 mm Hg and VA was 20/150.

Case 2. An 87-year-old woman (patient 5) with a history of primary open-angle glaucoma and longstanding vision loss in her left eye from wet, age-related macular degeneration was found to have similar exudative changes in her right eye. Visual acuity was 20/100 OD and counting fingers OS, and further examination revealed classic choroidal neovascularization and subretinal hemorrhage extending beneath the right fovea. The patient was scheduled for photodynamic therapy; however, the treatment session could not be completed because she had severe back pain. Two months later, her VA had deteriorated to 20/200 and she was treated with IVT injection with subsequent improvement in her VA to 20/60. The patient's IOP increased from 15 mm Hg pre-IVT to 23 mm Hg but was controlled with brimonidine only. Four months later, a recurrence of choroidal neovascularization was observed and a second IVT treatment administered. During the following 6 months, the patient's IOP continued to rise despite maximum medical therapy, leading to the decision to perform a trabeculectomy, which resulted in successful control of the IOP. This patient received a third IVT treatment 8 months later without any associated elevation in IOP on this occasion. At her latest visit, her VA was 20/60 and IOP was 16 mm Hg.


For more than 50 years steroids have been known to elevate the IOP in sensitive individuals6 presumably because of increased outflow resistance induced by biochemical and morphological changes in the trabecular meshwork.7 Given that patients who have undergone filtering surgery have an alternate outflow pathway, it is possible that their IOP should not be largely affected by administration of IVT. This assumption has found some confirmation in this small retrospective study where the mean difference between pre-IVT and maximum post-IVT IOP was 1 mm Hg. The results contrast dramatically with the reported mean IOP increase of 8 mm Hg observed in normal and medically controlled glaucomatous eyes treated with IVT injection.5

Two of our patients did not undergo filtering surgery until after their first IVT treatment. Both patients were satisfied with the visual results achieved after IVT and sought additional injections despite the increase in IOP they experienced.

A definitive conclusion about the safety of treating surgically controlled glaucoma patients with IVT injection cannot be reached from small case series; however, because a history of primary open-angle glaucoma usually constitutes an exclusion criterion for large randomized studies,8 we believe that our experience may be of benefit when choosing a treatment strategy for patients with macular disorders and functioning bleb or tube shunt.

Correspondence: Dr Gao, Department of Ophthalmology, Indiana University School of Medicine, 702 Rotary Cir, Indianapolis, IN 46202 (

Financial Disclosure: None reported.

Danis  RPCiulla  TAPratt  LMAnliker  W Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.  Retina 2000;20244- 250PubMedGoogle ScholarCrossref
Martidis  ADuker  JSGreenberg  PB  et al.  Intravitreal triamcinolone for refractory diabetic macular edema.  Ophthalmology 2002;109920- 927PubMedGoogle ScholarCrossref
Park  CHJaffe  GJFekrat  S Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion.  Am J Ophthalmol 2003;136419- 425PubMedGoogle ScholarCrossref
Jonas  JBDegenring  RFKreissing  IAkkoyun  IKamppeter  BA Intraocular pressure elevation after intravitreal triamcinolone acetonide injection.  Ophthalmology 2005;112593- 598PubMedGoogle ScholarCrossref
Smithen  LMOber  MDMaranan  LSpaide  RF Intravitreal triamcinolone acetonide and intraocular pressure.  Am J Ophthalmol 2004;138740- 743PubMedGoogle ScholarCrossref
Schwartz  B The response of ocular pressure to corticosteroids.  Int Ophthalmol Clin 1966;6929- 989PubMedGoogle ScholarCrossref
Wordinger  RJClark  AF Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma.  Prog Retin Eye Res 1999;18629- 667PubMedGoogle ScholarCrossref
 Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study inclusion/exclusion criteria. on October 6, 2006